MRD Testing Presents Challenges and Opportunities in Breast Cancer Care

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.

Related Keywords

Texas ,United States ,Miami ,Florida ,Dallas ,Eli Lilly ,Daiichi Sankyo ,Genentech Roche ,Heather Mcarthur ,Astrazeneca ,Department Of Internal Medicine ,Pfizer ,Amgen ,Syndax Pharmaceuticals ,Breast Cancer Program ,Clinical Breast Cancer Research ,Bristol Myers Squibb ,Spectrum Pharmaceuticals ,Annual Miami Breast Cancer ,Internal Medicine ,Komen Distinguished Chair ,Comprehensive Cancer Center ,Metastatic Success ,Disease Recurrence With ,Early Stage Breast ,Seattle Genetics ,International Association ,